Cover Image
市場調查報告書

EpiCast Report:特發性肺纖維化(IPF)的免疫學的預測

EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2025

出版商 GlobalData 商品編碼 268835
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:特發性肺纖維化(IPF)的免疫學的預測 EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2025
出版日期: 2016年06月07日 內容資訊: 英文 55 Pages
簡介

全球主要6個國家的特發性肺纖維化(IPF)的發病數量,預計2012∼2022年以年平均(年複合成長率)2.01%增加,2022年將達到45,718件。

本報告提供全球主要6個國家(美國·法國·德國·義大利·西班牙·英國)的特發性肺纖維化(以下IPF)的發病情形與今後預測相關分析,疾病的特徵,及目前患病·普及情形,今後10年的發病數量的預測值等等的調查評估,並將其結果為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 概況
  • 相關調查

第3章 免疫學

  • 疾病的背景情況
  • 風險要素和合併症
    • 長期的吸煙者之間不能發現IPF的風險
    • 一般的職場的二手煙吸入,為各種職業人員帶來很大的風險
    • 胃食道逆流(GER),是IPF患者常見的疾病
  • 全球各國趨勢
    • 美國
    • EU主要5個國家
  • 預測手法
    • 利用的資訊來源
    • 預測的假設·手法
    • 未利用的資訊來源
  • IPF的免疫學的預測:今後10年
    • 發病率(整體)
    • 發病率(各年齡層)
    • 發病率(男女)
    • 得病率(整體)
    • 得病率(各年齡層)
    • 得病率(男女)
  • 議論
    • 免疫學的趨勢相關結論
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER121-16

The American Thoracic Society (ATS) defines IPF as a chronic, fibrosing interstitial pneumonia of unknown cause, which occurs primarily in older adults. IPF is characterized by variable degrees of inflammation and scarring and is associated with a histologic or radiologic pattern of usual interstitial pneumonia (UIP). IPF is the most common form of idiopathic interstitial pneumonia, having the worst prognosis, and only three to five years of median survival. IPF is more common in men and the incidence and prevalence of IPF typically increases with advancing age.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of IPF will increase from 53,139 cases in 2015 to 62,258 cases in 2025, at an Annual Growth Rate (AGR) of 1.72%. The US will have the highest number of diagnosed incident cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest. The diagnosed prevalent cases of IPF will also increase from 118,943 cases in 2015 to 137,984 cases in 2025, at an AGR of 1.60%. The US will have the highest number of diagnosed prevalent cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest.

For this analysis, GlobalData epidemiologists used data from large comprehensive healthcare databases and country-specific studies published in peer-reviewed journals to estimate the diagnosed incident and diagnosed prevalent cases of IPF in addition to sources that provided data for cases confirmed through both biopsy of the lung and HRCT. Diagnosed incident and diagnosed prevalent cases were further segmented by age and sex to provide more detailed characteristics regarding the diseased population. The use of studies with consistent methodology across the 7MM provides a significant measure to compare the underlying burden of IPF across the 7MM. Additionally, GlobalData epidemiologists provided the diagnosed incident and diagnosed prevalent cases of IPF in the 7MM, except Japan, segmented by severity (mild, moderate, and severe) based on GAP index, which can be of importance for predicting the prognosis and course of treatment.

Scope

  • The Idiopathic Pulmonary Fibrosis (IPF) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for IPF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident and diagnosed prevalent cases of IPF segmented by sex, age (in five-year increments beginning at 18 years and ending at =85 years), and severity in these markets.
  • The IPF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The IPF EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global IPF market.
  • Quantify patient populations in the global IPF market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for IPF therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Epidemiology

  • 2.1. Risk Factors and Comorbidities
  • 2.2. Global Trends
    • 2.2.1. Incidence
    • 2.2.2. Prevalence
  • 2.3. Forecast Methodology
    • 2.3.1. Sources Used
    • 2.3.2. Forecast Assumptions and Methods
    • 2.3.3. Sources Not Used
  • 2.4. Epidemiological Forecast for IPF (2015-2025)
    • 2.4.1. Diagnosed Incident Cases
    • 2.4.2. Diagnosed Prevalent Cases
    • 2.4.3. IPF Mortality
  • 2.5. Discussion
    • 2.5.1. Epidemiological Forecast Insight
    • 2.5.2. Limitations of the Analysis
    • 2.5.3. Strengths of the Analysis

3. Appendix

  • 3.1. Bibliography
  • 3.2. About the Authors
    • 3.2.1. Epidemiologist
    • 3.2.2. Reviewers
    • 3.2.3. Global Director of Therapy Analysis and Epidemiology
    • 3.2.4. Global Head of Healthcare
  • 3.3. About GlobalData
  • 3.4. About EpiCast
  • 3.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities of IPF
  • Table 2: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of IPF
  • Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF
  • Table 4: 7MM, except Japan, Sources Used to Forecast Severity Segmentation of Diagnosed Incident Cases and Diagnosed Prevalent Cases of IPF
  • Table 5: 7MM, Sources Used to Forecast IPF Deaths
  • Table 6: 7MM, Sources Not Used in the Epidemiological Analysis of IPF
  • Table 7: 7MM, Diagnosed Incident Cases of IPF, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 8: 7MM, Age-Specific Diagnosed Incident Cases of IPF, Both Sexes, N (Row %), 2015
  • Table 9: 7MM, Sex-Specific Diagnosed Incident Cases of IPF, Ages ≥18 Years, N (Row %), 2015
  • Table 10: 7MM, Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 11: 7MM, Age-Specific Diagnosed Prevalent Cases of IPF, Both Sexes, N (Row %), 2015
  • Table 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, N (Row %), 2015
  • Table 13: 7MM, IPF Deaths, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 14: 7MM, Age-Specific IPF Deaths, Both Sexes, N (Row %), 2015
  • Table 15: 7MM, Sex-Specific IPF Deaths, Ages ≥18 Years, N (Row %), 2015

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of IPF, Ages ≥18 Years, Both Sexes, N, 2015-2025
  • Figure 2: 7MM, Age-Specific Diagnosed Incident Cases of IPF, Both Sexes, N, 2015
  • Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of IPF, Ages ≥18 Years, 2015
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of IPF, Ages ≥18 Years, N, 2015
  • Figure 5: US and 5EU, Diagnosed Incident Cases of IPF by Severity, Both Sexes, Ages ≥18, 2015
  • Figure 6: 7MM, Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
  • Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of IPF, Both Sexes, N, 2015
  • Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, 2015
  • Figure 9: 7MM, Age-Standardized Diagnosed Prevalence of IPF, Ages ≥18 Years, N, 2015
  • Figure 10: US and 5EU, Diagnosed Prevalent Cases of IPF by Severity, Both Sexes, Ages ≥18 Years, 2015
  • Figure 11: 7MM, IPF Deaths, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
  • Figure 12: 7MM, Age-Specific IPF Deaths, Both Sexes, N, 2015
  • Figure 13: 7MM, Sex-Specific IPF Deaths, Ages ≥18 Years, 2015
Back to Top